**Name of Journal: *World Journal of Gastroenterology***

**Manuscript NO: 37881**

**Manuscript Type: ORIGINAL ARTICLE**

***Retrospective Study***

**Fecal microbial dysbiosis in chinese patients with inflammatory bowel disease**

Ma HQ *et al*. Fecal microbial dysbiosis in IBD

Hai-Qin Ma, Ting-Ting Yu, Xiao-Jing Zhao, Yi Zhang, Hong-Jie Zhang

**Hai-Qin Ma, Ting-Ting Yu, Xiao-Jing Zhao, Yi Zhang, Hong-Jie Zhang,** Department of Gastroenterology, First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, Jiangsu Province, China

**ORCID number:** Hai-Qin Ma (0000-0002-2900-5994); Ting-Ting Yu (0000-0003-3433-9013); Xiao-Jing Zhao (0000-0001-5156-3864); Yi Zhang (0000-0002-3072-6043); Hong-Jie Zhang (0000-0003-4497-0503).

**Author contributions:** Ma HQ and Zhang HJ conceived the study; Ma HQ and Yu TT performed the research; Zhao XJ and Zhang Y analyzed the data; Ma HQ wrote this manuscript; Zhang HJ supervised the report.

**Supported by** the National Natural Science Foundation of China, No. 81470827.

**Institutional review board statement:** This study was reviewed and approved by the Ethics Committee of the First Affiliated Hospital of Nanjing Medical University.

**Informed consent statement:** All study participants provided informed written consent prior to study enrollment.

**Conflict-of-interest statement:** All authors declare no conflicts-of-interest related to this article.

**Data sharing statement:** No additional data are available.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Unsolicited manuscript

**Correspondence to: Hong-Jie Zhang, MD, PhD, Professor,** Department of Gastroenterology, First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, Jiangsu Province, China. hjzhang06@163.com

**Telephone:** +86-25-83718836-6920

**Fax:** +86-25-83674636

**Received:** January 10, 2018

**Peer-review started:** January 10, 2018

**First decision:** February 5, 2018

**Revised:** March 5, 2018

**Accepted:** March 7, 2018

**Article in press:**

**Published online:**

**Abstract**

***AIM***

To analyze the alterations of fecal microbiota in Chinese patients with inflammatory bowel disease (IBD).

***METHODS***

Fecal samples from 15 patients with Crohn’s disease (CD) (11 active CD, 4 inactive CD), 14 patients with active ulcerative colitis (UC) and 13 healthy individuals were collected and subjected to 16S ribosomal DNA (rDNA) gene sequencing. The V4 hypervariable regions of 16S rDNA gene were amplified from all samples and sequenced by the Illumina MiSeq platform. Quality control and operational taxonomic units (OTUs) classification of reads were calculated with QIIME software. Alpha diversity and beta diversity were displayed with R software.

***RESULTS***

Community richness (chao) and microbial structure in both CD and UC were significantly different from those in normal controls. At the phyla level, analysis of the microbial compositions revealed a significantly greater abundance of *Proteobacteria* in IBD as compared to that in controls. At the genera level, 8 genera in CD and 23 genera in UC (in particular, the *Escherichia* genus) showed significantly greater abundance as compared to that in normal controls. The relative abundance of *Bacteroidetes* in the active CD group was markedly lower than that in the inactive CD group. The abundance of *Proteobacteria* in patients with active CD was nominally higher than that in patients with inactive CD; however, the difference was not statistically significant after correction. Furthermore, the relative abundance of *Bacteroidetes* showed a negative correlation with the Crohn’s disease activity index scores.

***CONCLUSION***

Our study profiles specific characteristics and microbial dysbiosis in the gut of Chinese patients with IBD. *Bacteroidetes* may have a negative impact on inflammatory development.

**Key words:** Crohn’s disease; Ulcerative colitis; Microbial dysbiosis; Chinese; 16S ribosomal DNA

**© The Author(s) 2018.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Intestinal microbiota plays an important role in the pathogenesis of inflammatory bowel disease (IBD). However, there are few data on global alteration of microbiota in Chinese patients. In this study, fecal samples were subjected to 16S ribosomal DNA sequencing. Community richness and microbial structure in IBD were significantly different from those in normal controls. The relative abundance of *Bacteroidetes* in the active Crohn’s disease (CD) group was significantly lower than that in the inactive CD group, and it showed a negative correlation with Crohn’s disease activity index, which indicates that *Bacteroidetes* may have a negative impact on inflammatory development.

Ma HQ, Yu TT, Zhao XJ, Zhang Y, Zhang HJ. Fecal microbial dysbiosis in Chinese patients with inflammatory bowel disease. *World J Gastroenterol* 2018; In press**INTRODUCTION**

Inflammatory bowel disease (IBD) is characterized by chronic relapsing inflammation of the gastrointestinal tract and includes two main clinical phenotypes: Crohn’s disease (CD) and ulcerative colitis (UC). The etiopathogenesis of IBD is not completely understood. Several disease susceptibility genes, such as *NOD2*, *ATG16L1* and *IRGM* have been implicated in its pathogenesis[1]. However, the rapid increase in the incidence of IBD cannot be explained by genetic factors alone; an accumulating body of evidence indicates that environmental factors play a key role in the development of IBD by triggering intestinal microbiota dysbiosis[2].

Currently available data from experimental models and clinical studies suggest that intestinal microbiota plays an important role in the pathogenesis of IBD[3]. The alterations in intestinal microbiota related to IBD include decrease in *Bacteroides, Firmicutes, Clostridia, Ruminococcaceae, Bifidobacterium, Lactobacillus*, and *Faecalibacterium prausnitzii,* but increase in *Gamma Proteobacteria* and presence of *Fusobacterium* and *Escherichia* *coli*, especially *adherent-invasive* *E. coli* (AIEC). In addition, IBD is also associated with alterations in the microbial metabolic functions, including decrease of short-chain fatty acids (SCFAs) and amino acid biosynthesis, and increase of auxotrophy, amino acid and sulfate transport, oxidative stress, and type II secretion system[4-7].

With respect to changes (increase or decrease) in intestinal microbiota in IBD patients, some conflicting findings have been reported for several bacteria, including *Bifidobacterium, Clostridiales, Clostridium difficile, Campylobacter, Helicobacter* and *Faecalibacterium prausnitzii*[8]. For example, the levels of *F. prausnitzii* in IBD patients were found to be reduced in several studies[9-11]. However, one study of de-novo pediatric IBD revealed an increase in *F. prausnitzii* in CD, but not in UC[12]. Another study of twins showed an increase in *F. prausnitzii* in patients with colonic CD, but a decrease of *F. prausnitzii* in patients with ileal CD[13].

The intestinal microbiota of Western IBD patients has been extensively studied. However, the intestinal microbial profiles of Chinese IBD patients are not well characterized[14]. In the present study, we profiled and compared the fecal microbial community of IBD patients at different disease stages and healthy controls by using 16S rDNA amplicon-based analysis.

**MATERIALS AND METHODS**

***Study population***

Twenty-nine IBD patients (11 active CD, 4 inactive CD and 14 active UC patients) who regularly visited the First Affiliated Hospital of Nanjing Medical University (Jiangsu, China) from 2014 to 2016 were recruited in the study. The diagnosis of IBD was based on standard clinical, endoscopic, radiological, and histological criteria[15]. The control group consisted of gender- and age-matched healthy subjects. Patients with IBD who met any of the following criteria were excluded: (1) use of antibiotics, probiotics, or prebiotics in the 3-mo period immediately preceding the sampling time point; (2) current infectious diarrhea; and (3) malignancy. UC activity was evaluated using the Mayo Score[16]; active UC was defined as ulcerative colitis disease activity index > 2. Activity of CD was scored by Crohn’s disease activity index (CDAI)[17]; active CD was defined as a CDAI > 150. Written informed consent was obtained from all subjects prior to their enrollment and the study was approved by the Ethics Committee at the First Affiliated Hospital of Nanjing Medical University, Jiangsu, China.

***Fecal sample collection and extraction of genome DNA***

Fecal samples were collected from all subjects and subsequently stored at -80 °C within 2 h to prevent exposure of anaerobic bacteria to oxygen and to avoid bacterial overgrowth prior to DNA extraction. Genomic DNA was extracted from fecal samples using the QIAamp DNA Stool Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. 200mg of feces was added to a 2-mL screw cap vial containing 300 mg of 0.1-mm glass beads (Sigma, St. Louis, Missouri) which was maintained on ice. The samples were added of 1.4 mL ASL buffer and then subjected to bead beating (45 s, speed 6.5) twice using a FastPrep-24 machine (MP Biomedicals, Solon, Oh, United States) before the initial incubation for heat and chemical lysis at 95 °C for 5 min. Subsequent DNA extraction was performed following the QIAamp kit protocol for pathogen detection.

***Sequencing***

16S rDNA genes of V4 regions were amplified using specific primer with the barcode. All PCR reactions were carried out with Phusion® High-Fidelity PCR Master Mix (New England Biolabs). The same volume of 1X loading buffer (containing SYB green) was mixed with PCR products and electrophoresis was done on 2% agarose gel for detection. Samples with bright main strip between 400-450 bp were chosen for further experiments. PCR products were mixed in equidensity ratios. The mixture of PCR products was subsequently purified with Qiagen Gel Extraction Kit (Qiagen, Germany). Sequencing libraries were generated using TruSeq® DNA PCR-Free Sample Preparation Kit (Illumina, United States) following manufacturer's recommendations and index codes were added. The library quality was assessed on the Qubit@ 2.0 Fluorometer (Thermo Scientific) and Agilent Bioanalyzer 2100 system. Finally, the library was sequenced on an Illumina MiSeq platform and 250 bp paired-end reads were generated.

***Data analysis***

Paired-end reads were assigned to samples based on their unique barcode and truncated by cutting off the barcode and primer sequence. Paired-end reads were merged using FLASH (V1.2.7, <http://ccb.jhu.edu/software/FLASH/>)[18], which was designed to merge paired-end reads when at least some of the reads overlapped the read generated from the opposite end of the same DNA fragment, and the splicing sequences were called raw tags. Quality filtering of the raw tags was performed under specific filtering conditions to obtain high-quality clean tags[19] according to the QIIME (V1.7.0, <http://qiime.org/index.html>)[20] quality controlled process. The tags were compared with the reference database (Gold database, <http://drive5.com/uchime/uchime_download.html>) using UCHIME algorithm (UCHIME Algorithm, <http://www.drive5.com/usearch/manual/uchime_algo.html>)[21] to detect chimera sequences, and then the chimera sequences were removed[22]. Finally the effective tags were obtained. Analysis of sequences was performed with Uparse software (Uparse v7.0.1001, <http://drive5.com/uparse/>)[23]. Sequences with ≥ 97% similarity were assigned to the same OTUs. Representative sequence for each OTU was screened for further annotation. For each representative sequence, the GreenGene Database (<http://greengenes.lbl.gov/cgi-bin/nph-index.cgi>)[24] was used based on the RDP classifier (version 2.2, <http://sourceforge.net/projects/rdp-classifier/>)[25] algorithm to annotate taxonomic information. In order to study phylogenetic relationship of different OTUs, and the difference of the dominant species in different samples (groups), multiple sequence alignment were conducted using the MUSCLE software (version 3.8.31, <http://www.drive5.com/muscle/>)[26]. OTUs abundance information was normalized using a standard sequence number corresponding to the sample with the least sequences. Subsequent analysis of alpha diversity and beta diversity were all performed based on this output normalized data. Alpha diversity and beta diversity were calculated with QIIME (version 1.7.0) and displayed with R software (version 2.15.3). Statistical analysis was performed using Statistical Package for Social Sciences version 19.0 (SPSS Inc., Chicago, IL, United States). The microbiota data and community estimates were analyzed by Kruskal–Wallis one-way analysis of variance to compare median values of microbiota data between CD, UC and controls. Spearman correlation analysis was used to analyze the correlation between intestinal bacterial abundance and intestinal inflammatory status. *P* values were corrected for multiple comparisons using false discovery rate (FDR); *P* < 0.05 was considered statistically significant.

**RESULTS**

***Patients’ characteristics and sequencing data***

Fecal samples from patients with active CD (*n* = 11), inactive CD (*n* = 4), active UC (*n* = 14), and 13 healthy individuals were analyzed in the current study. The median disease duration in patients with CD and UC was 10 (range: 3-48) and 30 (range: 2-93) months, respectively. Detailed clinical characteristics of the study subjects are presented in Table 1.

Paired-end reads were generated with Illumina MiSeq platform. The reads with sequencing adapters, N base, poly base, and low quality were filtered out with default parameters. High quality paired-end reads were combined to tags based on overlaps. A total of 1747775 tags were obtained with an average of 41613 tags per sample; the average length was 252 bp. Filtered tags were clustered into operational taxonomic units (OTUs) at 97% similarity and a total of 878 OTUs were generated from 42 samples (see supplementary file 1).

***Characteristics of the microbial community in IBD patients and controls***

When comparing bacterial alpha diversity, including community richness (observed species, chao, and ace) and diversity (Shannon and Simpson) between CD, UC, and control groups, we found overall differences with respect to each diversity index (Figure 1). Significant differences (*P* < 0.05) with respect to community richness (chao) were observed both between CD and controls and between UC and controls. The observed species and ace indices of CD patients were lower than those of controls; however, the differences were not statistically significant (*P* < 0.05). Moreover, the pattern of richness was found to be similar in CD and UC. When considering the species diversity of microbiota (Shannon and Simpson), the differences between each group were not statistically significant.

We subsequently surveyed the alpha diversity in IBD patients at different disease stages (see supplementary Figure 1). Generally, the richness indices in IBD patients showed a decreasing trend (controls > inactive CD > active CD), but the between-group differences were not statistically significant. However, the diversity indices in IBD patients were not significantly different from those in controls.

***Microbial community structures in IBD are distinct from those in normal controls***

We used principal component analysis (PCA) to investigate the community structure of microbiota in CD, UC, and controls. We found that samples tended to cluster together based on disease; however, to a certain extent, there was an overlap between all groups. IBD samples were mostly distinct from those of normal controls, which indicated differences with respect to communitystructure of the microbiota between IBD and controls (Anosim: CD *vs* Control, *P* = 0.02; UC *vs* Control *P* = 0.001). However, samples of CD and UC were located closely, which suggested a similar bacterial community structure in the context of both CD and UC (Anosim: *P* = 0.133) (Figure 2A).

Next we visualized the PCA to compare the microbial structure in patients at different disease stages (Figure 2B). The results showed that samples could be well separated between active CD and controls (Anosim: *P* = 0.016) as well as between active CD and active UC (Anosim: *P* = 0.01). However, there were no distinct microbiota structural patterns apparent between active CD and inactive CD groups, although the samples seemed to be clearly separated (Anosim: *P* = 0.719). There was also no separation between inactive CD and controls (Anosim: *P* = 0.564) based on the PCA. Our results indicated that the bacterial community structure in active CD was different from that in active UC; however, there was no difference with respect to the alterations of bacterial community structure in fecal samples of the total UC and CD patients.

***Overall taxonomic analysis of IBD patients and controls***

Taxonomics composition distribution histograms of each sample were summarized at phyla level (Figure 3A). The dominant sequences belonged to 4 bacterial phyla (*Bacteroidetes*, *Firmicutes*, *Proteobacteria* and *Fusobacteria),* which accounted for over 97% of taxonomy generally (Figure 3B). Among all the relatively abundant dominant strains in IBD and normal controls, *Bacteroidetes* was, as a rule, the most abundant bacterial phylum.

Phylum-level analysis (Figure 3B, Table 2) revealed a nominal decrease in the relative abundance of *Bacteroidetes* in both CD and UC patients (CD *vs* Control, 47.49% *vs* 66.85%, *P* = 0.015; UC *vs* Control, 48.94% *vs* 66.85%, *P* = 0.019); however, these differences were not significant after adopting the false discovery rate (FDR). On the contrary, *Proteobacteria* was significantly increased in both CD and UC, as compared to that in controls (CD *vs* Control, 26.79% *vs*7.34%, *P* = 0.002; UC *vs* Control, 17.48% *vs* 7.34%, *P* = 0.005). In addition, no *Spirochaetes* phylum was detected in CD and controls but it was observed in UC (0.015%). Similarly, *Lentisphaerae* phylum was found in the control group (accounting for 0.031%), but almost none was found in patients with IBD.

At the genus level, the relative abundance of all genera varied between different samples (Figure 4A). The top 10 abundant genera in UC, CD, and controls were *Bacteroides*, *Escherichia*, *Faecalibacterium*, *Fusobacterium*, *Haemophilus*, *Lachnospira*, *Prevotella*, *Roseburia*, *Streptococcus*, and *Sutterella* (Figure 4B). Among these the relative abundance of *Escherichia* in CD and UC was significantly higher than that in controls. In addition, abundance of *Haemophilus* and *Prevotella* in both CD and UC patients was markedly lower than that in normal controls. Moreover, the abundance of *Haemophilus* in CD was dramatically lower than that in UC. Besides the top 10 abundant genera, the relative abundance of remaining genera was comparable between IBD patients and normal controls (Table 2). The abundance of 12 genera, *Butyricicoccus*, *Mitsuokella, 02d06*, *Actinomyces*, *Alistipes*, *Butyricimonas*, *Campylobacter*, *Desulfovibrio*, *Granulicatella*, *Lachnobacterium*, *Megamonas*, *Peptostreptococcus*, was significantly different after correction among each group within the community; the sequence percentages for each of these 12 genera were more than 0.01%.

***Taxonomic comparisons in IBD patients at different disease stages***

On analysis of the alterations at the phyla level between active CD and inactive CD, we found that the dominant bacterial phyla were the same as described earlier (accounting for over 99% of taxonomy), with the exception that *Fusobacteria* was replaced by *Actinobacteria* in inactive CD (Figure 3B, Table 2). However, the abundance of *Bacteroidetes* was dramatically decreased in active CD group as compared to that in the inactive CD group (CD.A *vs* CD.I, 38.79% *vs* 71.41%, *P* = 0.001). The abundance of *Proteobacteria* was just nominally increased in active CD as compared to that in inactive CD (*P* = 0.023), which did not hold significance after correction. Similarly, no differences were detected with respect to the remaining dominant bacteria between active CD and inactive CD. Microbiota in active CD and active UC were found to be similar at the phyla level.

We then investigated the genera with percentages of sequences > 0.01% of community in different phases of IBD and found that the abundance of *Bacteroides* and *Prevotella* in active CD were only nominally different from that in inactive CD. However, *Desulfovibrio*, *02d06*, *Epulopiscium*, and *Sarcina* detected in active CD were markedly higher than that in active UC, while *Haemophilus* was markedly lower than that in active UC (Table 2).

***Association between the inflammatory index of CD patients and microbiome***

We assessed the correlation between the relative abundance of *Bacteroidetes* and CDAI scores of each CD patient; surprisingly, we found a negative correlation between the two (*r* = -0.538, *P* = 0.039) (Figure 5A). On the contrary, there was a trend of positive correlation between the abundance of *Proteobacteria* and CDAI (*r* = 0.250, *P* = 0.369); however, the correlation was not statistically significant.

Next, we analyzed the correlation between microbial composition and disease severity. Patients with mild and moderate CD had notably decreased levels of *Bacteroidetes* as compared to that in patients with inactive CD; however, no significant difference in this respect was noted between patients with mild and moderate CD (Figure 5B). Interestingly, *Proteobacteria* exhibited a noteworthy trend (controls < inactive CD < mild CD < moderate CD); however, the trend did not attain statistical significance (Figure 5C).

***Effect of age and gender on intestinal microbial compositions***

Although IBD mostly occurs in young adults (20-30 years old), it can happen at any age. In the present research, no correlation was observed between microbial composition and age (see supplementary Figure 2). Considering that most participants in our study (with the exception of one patient aged 14 years with UC) were adults, we divided the participants into two groups: age < 40 years and age > 40 years. However, no significant difference in microbial compositions was observed between the two groups (see supplementary Table 1). On subgroup analysis based on gender, no notable differences were observed between male and female patients in either subject subgroup (see supplementary Table 2).

**DISCUSSION**

IBD is one of the most frequently studied human diseases linked to the gut microbiota. Distinctive microbial composition and its interaction with the host immunological response are believed to play a critical role in the pathogenesis of IBD[27,28]; however, several aspects of the relationship are not well-characterized. In this study, we demonstrated differences with respect to fecal microbiota between Chinese IBD patients and healthy controls based on 16S rDNA sequencing analysis.

The dominant dysbiosis pattern unraveled by the present study was the decrease in community abundance of fecal microbiota both in CD and UC patients; while microbial diversity in CD patients was lower than that in controls, the difference was not statistically significant. Previous studies have shown reduced diversity of fecal microbiota in both Western[29,30] and Chinese patients with IBD[14], as compared to that in healthy controls. These inconsistencies are likely attributable to differences with respect to study design, stage of disease, or technique employed to survey the gut microbiota. The reasons for the changes of diversity in these conditions are still not known. Indeed, despite general trends such as a reduction in diversity, the response to IBD may, to some extent, be subject-specific.

We analyzed the bacterial community structure of microbiota in IBD patients and healthy individuals. The results showed distinct differences both in CD and UC, as compared to controls; however, the microbiota were similar within CD and UC groups or within active CD and inactive CD groups, which were not structurally distinguishable according to PCA. These data were also consistent with the previous studies conducted in Chinese and Western populations[14,31]. However, Forbes *et al*[32] found a difference in the structure of microbiota between CD and UC. This result differed from those of other studies, as this study involved analysis of intestinal mucosa, while other studies were based on fecal analysis.

Detailed compositional alterations in fecal microbiota in IBD patients were detected at distinct taxonomic levels. The principle finding in our study was that the phylum *Proteobacteria* was significantly increased in IBD patients, which was in agreement with a consistent finding across published literature[33,34]. The genus *Escherichia*, especially *Escherichia coli* (data not shown), was also found to be notably higher in IBD patients as compared to that in normal controls. *Escherichia coli*, particularly adherent-invasive *E. coli* (AIEC), as an important pathobiont that may play a role in IBD development, has been isolated from ileal CD biopsy specimens[35]. The initial lesions in the colon mucosa can be aggravated by alpha-hemolysin secreted by *Escherichia coli*, which can damage host cell membranes and epithelial barrier[36].

Moreover, both *E coli* and *Campylobacter* (affiliated with *Proteobacteria*) are known to release cytolethal distending toxins, which leads to cell cycle arrest, chromatin fragmentation and apoptosis, all of which are involved in the pathogenesis of IBD[37].

In the present study, patients with IBD exhibited relatively less number of *Bacteroidetes* compared to that in controls. The lower proportion of *Bacteroidetes* was mainly attributable to notably reduced abundance of *Prevotella* genus. The results were largely similar to those of another study which employed 16S rDNA sequencing analysis[38]. Actually, alterations in *Bacteroidetes* in CD still remain controversial. Rehman *et al*[39] reported increased *Bacteroidetes* in CD patients and even demonstrated a notable increase in transcriptional activity, as compared to that in controls. Further studies are needed to clarify this issue. To minimize potential confounding factors, future studies should define gut dysbiosis in detail. Moreover, prospective cohort studies on newly diagnosed treatment-naïve patients will provide more definitive evidence in this respect.

In the present study, we documented increased abundance of *Haemophilus* and decreased *Desulfovibrio* (affiliated with *Proteobacteria*) in patients with UC. These findings were not observed in a previous study on fecal microbiota dysbiosis conducted by Chen *et al*[14] in Chinese patients with IBD. Recently, *Haemophilus* has been reported to contribute to oral dysbiosis in patients with IBD[40] and *Haemophilus* spp, like the *Enterobacteriaceae*, are well adapted to survive under conditions of increased oxidative stress[41]. To our knowledge, Rowan *et al*[42] demonstrated an increase of *Desulfovibrio* (sulfate-reducing bacteria) in patients with UC. *In vitro* studies have shown that 5-aminosalicylic acid (5-ASA) inhibits fecal sulfide production and fecal samples from patients not treated with this drug revealed higher levels of sulfide[43]. It is conceivable that all participants in the present study were treated with 5-ASA, which may have contributed to the opposite phenomenon.

In addition, the study found an abundance of *Butyricicoccus*, *Mitsuokella*, *02d06*, *Lachnobacterium* and *Megamonas* (all affiliated with *Clostridia* Class, *Firmicutes* phylum), which are obligate anaerobes. These were found significantly decreased in IBD patients in the current study. Dysanaerobiosis in patients with UC was observed recently[44] and there seems to be a shift from anaerobiosis in healthy state to dysanaerobiosis in IBD with an elevated oxygen level in the gut[45]. Furthermore, studies conducted on experimental colitis models showed decrease in obligate anaerobes of *Firmicutes* and increase in facultative anaerobes of *Proteobacteria*, which indicates a role of oxygen in gut dysbiosis[46]. In fact,both *Butyricicoccus* (affiliated with *Ruminococcaceae* Family) and *Lachnobacterium* (affiliated with *Lachnospiraceae* Family) produce short-chain fatty acids (SCFAs), which are known as the primary energy source for colonic epithelial cells[47] and were shown to induce the expansion of colonic regulatory T cells[48]. These alterations in microbial composition suggested that reduction in beneficial microbiota (*Clostridia* Class and SCFA-producing bacteria) is more associated with IBD patients compared to the increment of patho-bionts (*Escherichia* and *Campylobacter*).

When analyzing the fecal microbiota at different disease stages of IBD, only the abundance of *Bacteroidetes* was dramatically decreased in active CD as compared to that in inactive CD. About the relationship between microbiome and disease activity, we also found a negative correlation between the relative abundance of *Bacteroidetes* and CDAI in the present study. The relative abundance of *Bacteroidetes* in active CD patients was lower than that in inactive CD or controls, but the relative abundance of *Bacteroidetes* was similar between mild and moderate CD. All these findings suggest that *Bacteroidetes* may have a negative impact on inflammatory development.

Potential links between age or gender and microbial compositions have been suggested recently[49]. Gut microbiota vary in different age groups: infants, adults or the elderly. The microbiota in infants is often affected by the birth route, feeding patterns and illness history[50]. Not until adulthood does the microbiota become stable, complex and shows improved resilience against perturbations[51]. Then the stability decreases in the elderly (≥ 65 years of age)[52]. However, we did not find the effect of age and gender on microbiota in the current study. So a different role for the microbiota in disease initiation and progression should be researched.

Our study faces several limitations. First of all, due to the small sample number and relatively high variability of microbial composition in each group, some of the relative abundances of specific bacteria between groups could not reach statistically significant after adopting the FDR. Secondly, 16S rDNA sequencing mainly focuses on the taxonomic profiling rather than providing greater insight into the function of the intestinal microbiota in disease[53,54]. Thirdly, the nature and extent of difference between the fecal microbiota and mucosa-associated microbiota in IBD remains unclear. Controversy still exists between them because of different techniques used in separate studies[55]. Several studies indicated that the fecal microbiota and mucosa-associated microbiota were similar[13,56,57]. However, some studies have found a significant difference between them[14,58,59]. It seems that the fecal microbiota represents a combination of a separate nonadherent luminal population and shed mucosal bacteria[59]. Further study with a large population is required to confirm our data and mucosa-associated microbiota needs to be researched in Chinese patients with IBD.

In conclusion, we presented a comprehensive analysis of fecal microbiota in Chinese patients with IBD. Significant differences in microbial composition of patients with IBD and controls were observed. Additionally, the negative correlation between *Bacteroidetes* and CDAI suggested that *Bacteroidetes* might have a negative impact on development of inflammation.

**ARTICLE HIGHLIGHTS**

***Research background***

Inflammatory bowel disease (IBD) is generally defined by 2 nonspecific inflammatory disorders, Crohn’s disease (CD) and ulcerative colitis (UC), which are characterized by chronic persistent inflammation of the intestinal mucosa lining the intestinal tract. Recently, distinctive microbial composition and its interaction with the host immunological response are believed to play critical roles in the pathogenesis of IBD. Although the intestinal microbial composition of Western IBD patients has been extensively studied, there are conflicting reports about changes of the bacterial abundance. What’s more, the intestinal microbial profiles of Chinese IBD patients are not well characterized. In the present study, we use 16S rDNA amplicon-based analysis to analyze the alterations of fecal microbiota in Chinese patients with IBD.

***Research motivation***

Although the microbial community is gaining increasing attention for its influence on IBD, there is a lack of data on global alteration of microbiota in Chinese patients and the relationship is poorly understood. This study would characterize the important differences of fecal microbiota between Chinese IBD patients and healthy controls based on a 16S rDNA sequencing analysis, hoping for exploring which kinds of the microbiota could be involved in the pathogenesis of IBD or providing important references for diagnosis or treatment of IBD.

***Research objectives***

The research aimed to investigate the differences in quantity, diversity, and similarity of the fecal bacterial population taken from Chinese IBD patients at different stages of disease and healthy individuals.

***Research methods***

Twenty-nine IBD patients (11 active CD, 4 inactive CD and 14 active UC patients) from the First Affiliated Hospital of Nanjing Medical University (Jiangsu, China) and 13 gender and age well-matched healthy individuals were enrolled in the study. 16S rDNA amplicon-based sequencing was used to analyze the fecal microbiota of each sample.

***Research results***

In this study, community richness (chao) and microbial structure in IBD were significantly different from those in normal controls. The relative abundance of *Bacteroidetes* in the active CD group was significantly lower than that in the inactive CD group, and it showed a negative correlation with Crohn’s disease activity index (CDAI). At the phyla level, the abundance of *Proteobacteria* was significantly higher in IBD than in controls. At the genera level, 8 genera in CD and 23 genera in UC (in particular, the *Escherichia* genus) showed significantly greater abundance as compared to that in normal controls.

***Research conclusions***

Our study presented a comprehensive analysis of fecal microbiota in the gut of Chinese patients with IBD. Significant differences in microbial composition of patients with IBD and controls were observed. Additionally, the negative correlation between *Bacteroidetes* and CDAI suggested that *Bacteroidetes* might have a negative impact on development of inflammation.

***Research perspectives***

Fecal microbial examination is noninvasive and easily collected compared with the mucosal biopsy, which may increase the risk of unexpected bleeding.

However, the mucosa-associated microbiota is believed to directly affect epithelial and mucosal function. In the future, both the fecal and mucosa-associated microbiota should be investigated together to better understand the role of the intestinal microbiota in health and disease.

**ACKNOWLEDGMENTS**

The authors appreciate technical and statistical supports of BGI Tech Solution s Co.,Ltd (Shenzhen, China) and would like to express thanks.

**REFERENCES**

1 **Khor B**, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. *Nature* 2011; **474**: 307-317 [PMID: 21677747 DOI: 10.1038/nature10209]

2 **Molodecky NA**, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, Benchimol EI, Panaccione R, Ghosh S, Barkema HW, Kaplan GG. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. *Gastroenterology* 2012; **142**: 46-54.e42; quiz e30 [PMID: 22001864 DOI: 10.1053/j.gastro.2011.10.001]

3 **Knights D**, Lassen KG, Xavier RJ. Advances in inflammatory bowel disease pathogenesis: linking host genetics and the microbiome. *Gut* 2013; **62**: 1505-1510 [PMID: 24037875 DOI: 10.1136/gutjnl-2012-303954]

4 **Kostic AD**, Xavier RJ, Gevers D. The microbiome in inflammatory bowel disease: current status and the future ahead. *Gastroenterology* 2014; **146**: 1489-1499 [PMID: 24560869 DOI: 10.1053/j.gastro.2014.02.009]

5 **Krause DO**, Little AC, Dowd SE, Bernstein CN. Complete genome sequence of adherent invasive Escherichia coli UM146 isolated from Ileal Crohn's disease biopsy tissue. *J Bacteriol* 2011; **193**: 583 [PMID: 21075930 DOI: 10.1128/jb.01290-10]

6 **Kang S**, Denman SE, Morrison M, Yu Z, Dore J, Leclerc M, McSweeney CS. Dysbiosis of fecal microbiota in Crohn's disease patients as revealed by a custom phylogenetic microarray. *Inflamm Bowel Dis* 2010; **16**: 2034-2042 [PMID: 20848492 DOI: 10.1002/ibd.21319]

7 **Morgan XC**, Tickle TL, Sokol H, Gevers D, Devaney KL, Ward DV, Reyes JA, Shah SA, LeLeiko N, Snapper SB, Bousvaros A, Korzenik J, Sands BE, Xavier RJ, Huttenhower C. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. *Genome Biol* 2012; **13**: R79 [PMID: 23013615 DOI: 10.1186/gb-2012-13-9-r79]

8 **Li J**, Butcher J, Mack D, Stintzi A. Functional impacts of the intestinal microbiome in the pathogenesis of inflammatory bowel disease. *Inflamm Bowel Dis* 2015; **21**: 139-153 [PMID: 25248007 DOI: 10.1097/mib.0000000000000215]

9 **Willing B**, Halfvarson J, Dicksved J, Rosenquist M, Järnerot G, Engstrand L, Tysk C, Jansson JK. Twin studies reveal specific imbalances in the mucosa-associated microbiota of patients with ileal Crohn's disease. *Inflamm Bowel Dis* 2009; **15**: 653-660 [PMID: 19023901 DOI: 10.1002/ibd.20783]

10 **Machiels K**, Joossens M, Sabino J, De Preter V, Arijs I, Eeckhaut V, Ballet V, Claes K, Van Immerseel F, Verbeke K, Ferrante M, Verhaegen J, Rutgeerts P, Vermeire S. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. *Gut* 2014; **63**: 1275-1283 [PMID: 24021287 DOI: 10.1136/gutjnl-2013-304833]

11 **Sokol H**, Pigneur B, Watterlot L, Lakhdari O, Bermúdez-Humarán LG, Gratadoux JJ, Blugeon S, Bridonneau C, Furet JP, Corthier G, Grangette C, Vasquez N, Pochart P, Trugnan G, Thomas G, Blottière HM, Doré J, Marteau P, Seksik P, Langella P. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. *Proc Natl Acad Sci U S A* 2008; **105**: 16731-16736 [PMID: 18936492 DOI: 10.1073/pnas.0804812105]

12 **Hansen R**, Russell RK, Reiff C, Louis P, McIntosh F, Berry SH, Mukhopadhya I, Bisset WM, Barclay AR, Bishop J, Flynn DM, McGrogan P, Loganathan S, Mahdi G, Flint HJ, El-Omar EM, Hold GL. Microbiota of de-novo pediatric IBD: increased Faecalibacterium prausnitzii and reduced bacterial diversity in Crohn's but not in ulcerative colitis. *Am J Gastroenterol* 2012; **107**: 1913-1922 [PMID: 23044767 DOI: 10.1038/ajg.2012.335]

13 **Willing BP**, Dicksved J, Halfvarson J, Andersson AF, Lucio M, Zheng Z, Järnerot G, Tysk C, Jansson JK, Engstrand L. A pyrosequencing study in twins shows that gastrointestinal microbial profiles vary with inflammatory bowel disease phenotypes. *Gastroenterology* 2010; **139**: 1844-1854.e1 [PMID: 20816835 DOI: 10.1053/j.gastro.2010.08.049]

14 **Chen L**, Wang W, Zhou R, Ng SC, Li J, Huang M, Zhou F, Wang X, Shen B, A Kamm M, Wu K, Xia B. Characteristics of fecal and mucosa-associated microbiota in Chinese patients with inflammatory bowel disease. *Medicine (Baltimore)* 2014; **93**: e51 [PMID: 25121355 DOI: 10.1097/md.0000000000000051]

15 **Ouyang Q**, Tandon R, Goh KL, Pan GZ, Fock KM, Fiocchi C, Lam SK, Xiao SD. Management consensus of inflammatory bowel disease for the Asia-Pacific region. *J Gastroenterol Hepatol* 2006; **21**: 1772-1782 [PMID: 17074013 DOI: 10.1111/j.1440-1746.2006.04674.x]

16 **D'Haens G**, Sandborn WJ, Feagan BG, Geboes K, Hanauer SB, Irvine EJ, Lémann M, Marteau P, Rutgeerts P, Schölmerich J, Sutherland LR. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. *Gastroenterology* 2007; **132**: 763-786 [PMID: 17258735 DOI: 10.1053/j.gastro.2006.12.038]

17 **Best WR**, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. *Gastroenterology* 1976; **70**: 439-444 [PMID: 1248701]

18 **Magoč T**, Salzberg SL. FLASH: fast length adjustment of short reads to improve genome assemblies. *Bioinformatics* 2011; **27**: 2957-2963 [PMID: 21903629 DOI: 10.1093/bioinformatics/btr507]

19 **Bokulich NA**, Subramanian S, Faith JJ, Gevers D, Gordon JI, Knight R, Mills DA, Caporaso JG. Quality-filtering vastly improves diversity estimates from Illumina amplicon sequencing. *Nat Methods* 2013; **10**: 57-59 [PMID: 23202435 DOI: 10.1038/nmeth.2276]

20 **Caporaso JG**, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK, Fierer N, Peña AG, Goodrich JK, Gordon JI, Huttley GA, Kelley ST, Knights D, Koenig JE, Ley RE, Lozupone CA, McDonald D, Muegge BD, Pirrung M, Reeder J, Sevinsky JR, Turnbaugh PJ, Walters WA, Widmann J, Yatsunenko T, Zaneveld J, Knight R. QIIME allows analysis of high-throughput community sequencing data. *Nat Methods* 2010; **7**: 335-336 [PMID: 20383131 DOI: 10.1038/nmeth.f.303]

21 **Edgar RC**, Haas BJ, Clemente JC, Quince C, Knight R. UCHIME improves sensitivity and speed of chimera detection. *Bioinformatics* 2011; **27**: 2194-2200 [PMID: 21700674 DOI: 10.1093/bioinformatics/btr381]

22 **Haas BJ**, Gevers D, Earl AM, Feldgarden M, Ward DV, Giannoukos G, Ciulla D, Tabbaa D, Highlander SK, Sodergren E, Methé B, DeSantis TZ; Human Microbiome Consortium, Petrosino JF, Knight R, Birren BW. Chimeric 16S rRNA sequence formation and detection in Sanger and 454-pyrosequenced PCR amplicons. *Genome Res* 2011; **21**: 494-504 [PMID: 21212162 DOI: 10.1101/gr.112730.110]

23 **Edgar RC**. UPARSE: highly accurate OTU sequences from microbial amplicon reads. *Nat Methods* 2013; **10**: 996-998 [PMID: 23955772 DOI: 10.1038/nmeth.2604]

24 **DeSantis TZ**, Hugenholtz P, Larsen N, Rojas M, Brodie EL, Keller K, Huber T, Dalevi D, Hu P, Andersen GL. Greengenes, a chimera-checked 16S rRNA gene database and workbench compatible with ARB. *Appl Environ Microbiol* 2006; **72**: 5069-5072 [PMID: 16820507 DOI: 10.1128/aem.03006-05]

25 **Wang Q**, Garrity GM, Tiedje JM, Cole JR. Naive Bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy. *Appl Environ Microbiol* 2007; **73**: 5261-5267 [PMID: 17586664 DOI: 10.1128/aem.00062-07]

26 **Edgar RC**. MUSCLE: multiple sequence alignment with high accuracy and high throughput. *Nucleic Acids Res* 2004; **32**: 1792-1797 [PMID: 15034147 DOI: 10.1093/nar/gkh340]

27 **Sartor RB**. Microbial influences in inflammatory bowel diseases. *Gastroenterology* 2008; **134**: 577-594 [PMID: 18242222 DOI: 10.1053/j.gastro.2007.11.059]

28 **Swidsinski A**, Ladhoff A, Pernthaler A, Swidsinski S, Loening-Baucke V, Ortner M, Weber J, Hoffmann U, Schreiber S, Dietel M, Lochs H. Mucosal flora in inflammatory bowel disease. *Gastroenterology* 2002; **122**: 44-54 [PMID: 11781279]

29 **Manichanh C**, Rigottier-Gois L, Bonnaud E, Gloux K, Pelletier E, Frangeul L, Nalin R, Jarrin C, Chardon P, Marteau P, Roca J, Dore J. Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. *Gut* 2006; **55**: 205-211 [PMID: 16188921 DOI: 10.1136/gut.2005.073817]

30 **Ott SJ**, Musfeldt M, Wenderoth DF, Hampe J, Brant O, Fölsch UR, Timmis KN, Schreiber S. Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. *Gut* 2004; **53**: 685-693 [PMID: 15082587]

31 **Andoh A**, Imaeda H, Aomatsu T, Inatomi O, Bamba S, Sasaki M, Saito Y, Tsujikawa T, Fujiyama Y. Comparison of the fecal microbiota profiles between ulcerative colitis and Crohn's disease using terminal restriction fragment length polymorphism analysis. *J Gastroenterol* 2011; **46**: 479-486 [PMID: 21253779 DOI: 10.1007/s00535-010-0368-4]

32 **Forbes JD**, Van Domselaar G, Bernstein CN. Microbiome Survey of the Inflamed and Noninflamed Gut at Different Compartments Within the Gastrointestinal Tract of Inflammatory Bowel Disease Patients. *Inflamm Bowel Dis* 2016; **22**: 817-825 [PMID: 26937623 DOI: 10.1097/mib.0000000000000684]

33 **Man SM**, Kaakoush NO, Mitchell HM. The role of bacteria and pattern-recognition receptors in Crohn's disease. *Nat Rev Gastroenterol Hepatol* 2011; **8**: 152-168 [PMID: 21304476 DOI: 10.1038/nrgastro.2011.3]

34 **Sokol H**, Lepage P, Seksik P, Doré J, Marteau P. Temperature gradient gel electrophoresis of fecal 16S rRNA reveals active Escherichia coli in the microbiota of patients with ulcerative colitis. *J Clin Microbiol* 2006; **44**: 3172-3177 [PMID: 16954244 DOI: 10.1128/jcm.02600-05]

35 **Darfeuille-Michaud A**, Boudeau J, Bulois P, Neut C, Glasser AL, Barnich N, Bringer MA, Swidsinski A, Beaugerie L, Colombel JF. High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. *Gastroenterology* 2004; **127**: 412-421 [PMID: 15300573]

36 **Bücker R**, Schulz E, Günzel D, Bojarski C, Lee IF, John LJ, Wiegand S, Janßen T, Wieler LH, Dobrindt U, Beutin L, Ewers C, Fromm M, Siegmund B, Troeger H, Schulzke JD. α-Haemolysin of Escherichia coli in IBD: a potentiator of inflammatory activity in the colon. *Gut* 2014; **63**: 1893-1901 [PMID: 24534723 DOI: 10.1136/gutjnl-2013-306099]

37 **Smith JL**, Bayles DO. The contribution of cytolethal distending toxin to bacterial pathogenesis. *Crit Rev Microbiol* 2006; **32**: 227-248 [PMID: 17123907 DOI: 10.1080/10408410601023557]

38 **Lepage P**, Häsler R, Spehlmann ME, Rehman A, Zvirbliene A, Begun A, Ott S, Kupcinskas L, Doré J, Raedler A, Schreiber S. Twin study indicates loss of interaction between microbiota and mucosa of patients with ulcerative colitis. *Gastroenterology* 2011; **141**: 227-236 [PMID: 21621540 DOI: 10.1053/j.gastro.2011.04.011]

39 **Rehman A**, Lepage P, Nolte A, Hellmig S, Schreiber S, Ott SJ. Transcriptional activity of the dominant gut mucosal microbiota in chronic inflammatory bowel disease patients. *J Med Microbiol* 2010; **59**: 1114-1122 [PMID: 20522625 DOI: 10.1099/jmm.0.021170-0]

40 **Said HS**, Suda W, Nakagome S, Chinen H, Oshima K, Kim S, Kimura R, Iraha A, Ishida H, Fujita J, Mano S, Morita H, Dohi T, Oota H, Hattori M. Dysbiosis of salivary microbiota in inflammatory bowel disease and its association with oral immunological biomarkers. *DNA Res* 2014; **21**: 15-25 [PMID: 24013298 DOI: 10.1093/dnares/dst037]

41 **Harrison A**, Bakaletz LO, Munson RS Jr. Haemophilus influenzae and oxidative stress. *Front Cell Infect Microbiol* 2012; **2**: 40 [PMID: 22919631 DOI: 10.3389/fcimb.2012.00040]

42 **Rowan F**, Docherty NG, Murphy M, Murphy B, Calvin Coffey J, O'Connell PR. Desulfovibrio bacterial species are increased in ulcerative colitis. *Dis Colon Rectum* 2010; **53**: 1530-1536 [PMID: 20940602 DOI: 10.1007/DCR.0b013e3181f1e620]

43 **Pitcher MC**, Beatty ER, Cummings JH. The contribution of sulphate reducing bacteria and 5-aminosalicylic acid to faecal sulphide in patients with ulcerative colitis. *Gut* 2000; **46**: 64-72 [PMID: 10601057]

44 **Walujkar SA**, Dhotre DP, Marathe NP, Lawate PS, Bharadwaj RS, Shouche YS. Characterization of bacterial community shift in human Ulcerative Colitis patients revealed by Illumina based 16S rRNA gene amplicon sequencing. *Gut Pathog* 2014; **6**: 22 [PMID: 25018784 DOI: 10.1186/1757-4749-6-22]

45 **Rigottier-Gois L**. Dysbiosis in inflammatory bowel diseases: the oxygen hypothesis. *ISME J* 2013; **7**: 1256-1261 [PMID: 23677008 DOI: 10.1038/ismej.2013.80]

46 **Podolsky DK**. Inflammatory bowel disease (1) *N Engl J Med* 1991; **325**: 928-937 [PMID: 1881418 DOI: 10.1056/nejm199109263251306]

47 **Ahmad MS**, Krishnan S, Ramakrishna BS, Mathan M, Pulimood AB, Murthy SN. Butyrate and glucose metabolism by colonocytes in experimental colitis in mice. *Gut* 2000; **46**: 493-499 [PMID: 10716678]

48 **Smith PM**, Howitt MR, Panikov N, Michaud M, Gallini CA, Bohlooly-Y M, Glickman JN, Garrett WS. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. *Science* 2013; **341**: 569-573 [PMID: 23828891 DOI: 10.1126/science.1241165]

49 **Blaser MJ**, Falkow S. What are the consequences of the disappearing human microbiota? *Nat Rev Microbiol* 2009; **7**: 887-894 [PMID: 19898491 DOI: 10.1038/nrmicro2245]

50 **Dominguez-Bello MG**, Blaser MJ, Ley RE, Knight R. Development of the human gastrointestinal microbiota and insights from high-throughput sequencing. *Gastroenterology* 2011; **140**: 1713-1719 [PMID: 21530737 DOI: 10.1053/j.gastro.2011.02.011]

51 **Lozupone CA**, Stombaugh JI, Gordon JI, Jansson JK, Knight R. Diversity, stability and resilience of the human gut microbiota. *Nature* 2012; **489**: 220-230 [PMID: 22972295 DOI: 10.1038/nature11550]

52 **Claesson MJ**, Cusack S, O'Sullivan O, Greene-Diniz R, de Weerd H, Flannery E, Marchesi JR, Falush D, Dinan T, Fitzgerald G, Stanton C, van Sinderen D, O'Connor M, Harnedy N, O'Connor K, Henry C, O'Mahony D, Fitzgerald AP, Shanahan F, Twomey C, Hill C, Ross RP, O'Toole PW. Composition, variability, and temporal stability of the intestinal microbiota of the elderly. *Proc Natl Acad Sci U S A* 2011; **108 Suppl 1**: 4586-4591 [PMID: 20571116 DOI: 10.1073/pnas.1000097107]

53 **Meyer F**, Trimble WL, Chang EB, Handley KM. Functional predictions from inference and observation in sequence-based inflammatory bowel disease research. *Genome Biol* 2012; **13**: 169 [PMID: 23013527 DOI: 10.1186/gb4042]

54 **Presley LL**, Ye J, Li X, Leblanc J, Zhang Z, Ruegger PM, Allard J, McGovern D, Ippoliti A, Roth B, Cui X, Jeske DR, Elashoff D, Goodglick L, Braun J, Borneman J. Host-microbe relationships in inflammatory bowel disease detected by bacterial and metaproteomic analysis of the mucosal-luminal interface. *Inflamm Bowel Dis* 2012; **18**: 409-417 [PMID: 21698720 DOI: 10.1002/ibd.21793]

55 **De Cruz P**, Prideaux L, Wagner J, Ng SC, McSweeney C, Kirkwood C, Morrison M, Kamm MA. Characterization of the gastrointestinal microbiota in health and inflammatory bowel disease. *Inflamm Bowel Dis* 2012; **18**: 372-390 [PMID: 21604329 DOI: 10.1002/ibd.21751]

56 **van der Waaij LA**, Harmsen HJ, Madjipour M, Kroese FG, Zwiers M, van Dullemen HM, de Boer NK, Welling GW, Jansen PL. Bacterial population analysis of human colon and terminal ileum biopsies with 16S rRNA-based fluorescent probes: commensal bacteria live in suspension and have no direct contact with epithelial cells. *Inflamm Bowel Dis* 2005; **11**: 865-871 [PMID: 16189415]

57 **Bibiloni R**, Tandon P, Vargas-Voracka F, Barreto-Zuniga R, Lupian-Sanchez A, Rico-Hinojosa MA, Guban J, Fedorak R, Tannock GW. Differential clustering of bowel biopsy-associated bacterial profiles of specimens collected in Mexico and Canada: what do these profiles represent? *J Med Microbiol* 2008; **57**: 111-117 [PMID: 18065676 DOI: 10.1099/jmm.0.47321-0]

58 **Durbán A**, Abellán JJ, Jiménez-Hernández N, Ponce M, Ponce J, Sala T, D'Auria G, Latorre A, Moya A. Assessing gut microbial diversity from feces and rectal mucosa. *Microb Ecol* 2011; **61**: 123-133 [PMID: 20734040 DOI: 10.1007/s00248-010-9738-y]

59 **Eckburg PB**, Bik EM, Bernstein CN, Purdom E, Dethlefsen L, Sargent M, Gill SR, Nelson KE, Relman DA. Diversity of the human intestinal microbial flora. *Science* 2005; **308**: 1635-1638 [PMID: 15831718 DOI: 10.1126/science.1110591]

**P-Reviewer:** Naito Y, Zouiten-Mekki L **S-Editor:** Gong ZM

**L-Editor:** **E-Editor:**

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** China

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C, C

Grade D (Fair): 0

Grade E (Poor): 0



**Figure 1** **Alpha diversity indices boxplot, including community richness (observed species, chao, ace) and diversity (Shannon, Simpson) varied among each group.** A: observed species; B: chao; C: ace; D: Shannon; E: Simpson. a*P* < 0.05 *vs* Control. CD: Crohn’s disease; UC: ulcerative colitis. 

**Figure 2** **principal component analysis based on the overall structure of the fecal microbiota in the entire study population.** Each data point represents an individual sample. A: disease phenotype group; B: stages of disease group. CD: Crohn’s disease; UC: ulcerative colitis; CD.A: active CD; CD.I: inactive CD; UC.A: active UC.



**Figure 3 Taxonomic composition distribution in samples of phylum level.** A: individually; B: integrally. CD: Crohn’s disease; UC: ulcerative colitis; CD.A: active CD; CD.I: inactive CD; UC.A: active UC.



**Figure 4 A: The taxonomic composition distribution in samples of genus level; B: Genera shown represent the 10 most abundant genera of Crohn’s disease, ulcerative colitis and control.** a*P* < 0.05 *vs* Control, c*P* < 0.05 *vs* CD.CD: Crohn’s disease; UC: ulcerative colitis.



**Figure 5 Correlation of the relative abundance of *Bacteroidetes* and *Proteobacteria* with Crohn’s disease activity index scores (A).** *Bacteroidetes* (*r* = -0.538, *P* = 0.039); *Proteobacteria* (*r* = 0.250, *P* = 0.369); B: Microbial composition of *Bacteroidetes* in patients with inactive/mild/moderate CD and in Control; C: Microbial composition of *Proteobacteria* in patients with inactive/mild/moderate CD and in controls. a*P* < 0.05 *vs* Control; c*P* < 0.05 *vs* CD.mild; e*P* < 0.05 *vs* CD.moderate. CDAI: CD activity index; CD.I: inactive CD; CD.mild: mild CD; CD.moderate: moderate CD.

**Table 1 Clinical characteristics of enrolled patients *n* (%)**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **CD** | **UC** | **Control (n=13)** |
| *n* | 15 | 14 | 13 |
| Age, mean ± SD, yr | 37.7±13.0 | 37.5±17.1 | 39.8±14.3 |
| Sex, male/female | 11/4 | 7/7 | 10/3 |
| Disease duration (median, range), month | 10 (3-48) | 30 (2-93) | - |
| Smoking habits | 4 (26.7) | 1 (7.1) | 2 (15.4) |
| Abdominal surgery | 4 (26.7) | 0 | 0 |
| Montreal A (age of onset) |  |  |  |
| A1 (< 17) | 1 (6.7) | - | - |
| A2 (17-40) | 7 (46.7) | - | - |
| A3 (> 40) | 7 (46.7) | - | - |
| Montreal L (location) |  |  |  |
| L1 (ileal) | 8 (53.3) | - | - |
| L2 (colonic) | 1 (6.7) | - | - |
| L3 (ileocolonic) | 6 (40) | - | - |
| L4 (upper gastrointestinal tract) | 0 | - | - |
| Montreal B (behavior) |  |  |  |
| B1(nonstricturing, nonpenetrating) | 8 (53.3) | - | - |
| B2 (stricturing) | 6 (40) | - | - |
| B3 (penetrating) | 1 (6.7) | - | - |
| p (perianal disease) | 4 (26.7) | - | - |
| Montreal |  |  |  |
|  E1 ulcerative proctitis | - | 4 (28.6) | - |
|  E2 left sided ulcerative colitis | - | 5 (35.7) | - |
|  E3 extensive ulcerative colitis | - | 5 (35.7) | - |
| CDAI Score |  |  |  |
|  < 150  | 4 (26.7) | - | - |
|  150-220 | 5 (33.3) | - | - |
|  221-450 | 6 (40) | - | - |
|  > 450 | 0 | - | - |
| Mayo Score |  |  |  |
|  0-2 | - | 0 | - |
|  3-5 | - | 7 (50.0) | - |
|  6-10 | - | 5 (35.7) | - |
|  11-12 | - | 2 (14.3) | - |
| Therapy |  |  |  |
|  5-ASA | 14 (93.3) | 14 (100) | - |
|  Azathioprine | 2 (13.3) | 0 | - |
|  Steroids | 1 (6.7) | 6 (42.9) | - |
|  Infliximab | 0 | 0 | - |

CD: Crohn’s disease; UC: ulcerative colitis; CDAI: CD activity index.

**Table 2 Significant differences in microbial distribution of taxa (phylum and genus) in patients with inflammatory bowel disease**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **CD** | **UC** | **CD/UC** | **CD.A/CD.I** | **CD.A/UC.A** |
| ***Firmicutes*** |  |  |  |  |  |
| *Abiotrophia1* | ↑c |  |  |  |  |
| *Butyricicoccus* | ↓c |  | c3 |  |  |
| *RFN201* | ↑c |  | c2 |  |  |
| *Pseudoramibacter\_Eubacteriu1m\*\** | ↑b |  | c2 |  |  |
| *Holdemania1* |  | ↓c |  |  | c2 |
| *02d06* |  | ↓c | c2 |  | c2 |
| *Lachnobacterium* |  | ↓c |  |  |  |
| *Megamonas* |  | ↓c |  |  |  |
| *Mitsuokella* | ↓c | ↓c |  |  |  |
| *Granulicatella* |  | ↑b |  |  |  |
| *Peptostreptococcus* |  | ↑b |  |  |  |
| *Schwartzia1* |  | ↑b |  |  |  |
| *Moryella1* |  |  | c3 |  |  |
| *Staphylococcus1* |  |  | c3 |  | c3 |
| *Epulopiscium* |  |  |  |  | c2 |
| *Sarcina* |  |  |  |  | c2 |
| ***Bacteroidetes*** |  |  |  | b3 |  |
| *Alistipes*  |  | ↓c |  |  |  |
| *Butyricimonas*  |  | ↓c |  |  |  |
| *Capnocytophaga1* |  | ↑c | c3 |  | c3 |
| *Prevotella*  |  | ↓c |  |  |  |
| ***Proteobacteria*** | ↑b | ↑b |  |  |  |
| *Escherichia*  | ↑c | ↑b |  |  |  |
| *Haemophilus*  | ↓c |  | b3 |  | b3 |
| *Desulfovibrio*  |  | ↓c | b2 |  | c2 |
| *Oxalobacte1* |  | ↓c |  |  |  |
| *Janthinobacterium1* |  | ↑b | b3 |  |  |
| *Campylobacter*  |  | ↑b |  |  |  |
| *Cardiobacterium1* |  |  | c3 |  |  |
| *Lautropia1* |  |  | c3 |  |  |
| *Lupinus1* |  |  | c3 |  |  |
| *Shewanella1* |  |  | b3 |  |  |
| ***Actinobacteria*** |  |  |  |  |  |
| *Actinomyces*  |  | ↑c |  |  |  |
| *Eggerthella1* |  | ↑b |  |  |  |
| *Corynebacterium1* |  | ↑b | c3 |  | b3 |
| *Slackia1* |  |  | b2 |  | c2 |
| ***Synergistetes*** |  |  |  |  |  |
| *Pyramidobacter1* |  | ↓c |  |  |  |
| *Synergistes1* |  | ↓c |  |  |  |
| *TG51* |  |  | c3 |  |  |
| ***Spirochaetes*** |  | ↑c |  |  | c3 |
| ***Lentisphaerae*** |  | ↓c |  |  | c2 |
| *Victivallis1* | ↓c | ↓c |  |  |  |

↑ and ↓ relative to controls; 1relative abundance of genera < 0.01%; 2increase in value; 3decrease in value. a*P* < 0.05; b*P* < 0.01; c*P* < 0.001. CD: Crohn’s disease; UC: ulcerative colitis; IBD: inflammatory bowel disease; CD.A: active CD; CD.I: inactive CD; UC.A: active UC.